Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion products, ketamine microneedle patch and ketamine wearable pump device for mental health, neurological, and pain disorders Seeking FDA approval for the Company’s ketamine injection and infusion products for anesthesia and procedural sedation in 2023 TORONTO, Sept.


Previous articleReunion Neuroscience Inc. Appoints Greg Mayes as President and Chief Executive Officer
Next articlePT360 – Stephanie Wang – Kanna: Love and Wholeness Through Nature’s Alternative to MDMA